Mario Islas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mario Islas has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexis W. Thomas
Virginia G. Piper Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA
1 shared publication - Efrem S. Lim
School of Life Sciences, Arizona State University, Tempe, USA
1 shared publication - Gabrielle M. Hernandez Barrera
Virginia G. Piper Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA
1 shared publication - Joanna L. Kramer
Phoenix Children’s Hospital , Phoenix , AZ , USA
1 shared publication - LaRinda A. Holland
Center for Fundamental and Applied Microbiomics, The Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA
1 shared publication - Lora Nordstrom
Valleywise Health Medical Center, Phoenix, AZ 85008, USA
1 shared publication
Latest Publications
- Open Access
Influenza Virus Genomic Surveillance, Arizona, USA, 2023–2024
Influenza viruses are constantly evolving and are therefore monitored worldwide in the hope to reduce the burden of disease by annual updates to vaccine recommendations. We conducted genomic sequencing of 110 influenza A and 30 influenza B viruses from specimens collected between October 2023 and February 2024 in Arizona, USA. We identified mutations in the hemagglutinin (HA) antigenic sites as well as the neuraminidase (NA) gene in our samples. We also found no unique HA and NA mutations in vaccinated yet influenza-infected individuals. Real-time genomic sequencing surveillance is important to ensure influenza vaccine effectiveness.
Open AccessInfluenza Virus Genomic Surveillance, Arizona, USA, 2023–2024
Influenza viruses are constantly evolving and are therefore monitored worldwide in the hope to reduce the burden of disease by annual updates to vaccine recommendations. We conducted genomic sequencing of 110 influenza A and 30 influenza B viruses from specimens collected between October 2023 and February 2024 in Arizona, USA. We identified mutations in the hemagglutinin (HA) antigenic sites as well as the neuraminidase (NA) gene in our samples. We also found no unique HA and NA mutations in vaccinated yet influenza-infected individuals. Real-time genomic sequencing surveillance is important to ensure influenza vaccine effectiveness.